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18F-fluorodeoxyglucose positron emission tomography/
computed tomography and magnetic resonance imaging
in patients with liver metastases from uveal melanoma:
results from a pilot study
Victoria Orcurtoa, Alban Denysb, Verena Voelterc, Ann Schalenbourgd,
Pierre Schnyderb, Leonidas Zografosd, Serge Leyvrazc,
Angelika Bischof Delaloyea and John O. Priora
Purpose 18F-fluorodeoxyglucose (FDG) positron emission
tomography/computed tomography (PET/CT) and MRI are
used for detecting liver metastases from uveal melanoma.
The introduction of new treatment options in clinical trials
might benefit from early response assessment. Here, we
determine the value of FDG-PET/CT with respect to MRI at
diagnosis and its potential for monitoring therapy.
Material and methods Ten patients with biopsy-proven
liver metastases of uveal melanoma enrolled in a
randomized phase III trial (NCT00110123) underwent
both FDG-PET coupled with unenhanced CT and
gadolinium-diethylene triamine pentaacetic acid-enhanced
liver MRI within 4 weeks. FDG-PET and MRI were evaluated
blindly and then compared using the ratio of lesion to
normal liver parenchyma PET-derived standardized uptake
value (SUV). The influence of lesion size and response to
chemotherapy were studied.
Results Overall, 108 liver lesions were seen: 34 (31%) on
both modalities (1–18 lesions/patient), four (4%) by
PET/CT only, and 70 (65%) by MRI only. SUV correlated
with MRI lesion size (r=0.81, P<0.0001). PET/CT detected
26 of 33 (79%) MRI lesions of more than or equal to 1.2 cm,
whereas it detected only eight of 71 (11%) lesions of
less than 1.2 cm (P<0.0001). MRI lesions without PET
correspondence were small (0.6± 0.2 vs. 2.1± 1.1 cm,
P<0.0001). During follow-up (six patients, 30 lesions), the
ratio lesion-to-normal-liver SUV diminished in size-stable
lesions (1.90±0.64–1.46±0.50, P< 0.0001), whereas it
increased in enlarging lesions (1.56±0.40–1.99±0.56,
P= 0.032).
Conclusion MRI outweighs PET/CT for detecting small
liver metastases. However, PET/CT detected at least one
liver metastasis per patient and changes in FDG uptake not
related to size change, suggesting a role in assessing early
therapy response. Melanoma Res 00:000–000 c 2011
Wolters Kluwer Health | Lippincott Williams & Wilkins.
Melanoma Research 2011, 00:000–000
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Introduction
Uveal melanoma is the most common primary intraocular
malignancy in Caucasians, representing 70% of all ocular
tumors [1]. Median age at presentation is about 60 years
and reported annual incidence ranges from 5.3 to 10.9
cases per million in the USA and 2–8 cases per million in
Europe [2,3]. Owing to the lack of lymphatics in the eye,
metastatic spread of uveal melanoma is exclusively
hematogenous, predominantly to the liver (Z 95% of
metastatic patients) [4]. Approximately 1% of patients
have demonstrable liver metastases at presentation, and
up to 50% will ultimately develop hepatic metastases
within 10–15 years, suggesting the presence of subclinical
disease at the time of initial diagnosis [1]. The
mechanisms for this liver tropism is not yet under-
stood [4]. Other less common sites of metastasis are
lungs, bones, skin, lymph nodes, pancreas, heart, spleen,
adrenal glands, gastrointestinal tract, kidneys, ovaries, and
thyroid. Several clinical, histopathological, and cyto-
genetic characteristics are associated with poor prognosis
including chromosomal abnormalities, the most impor-
tant of which are monosomy 3, isochromosome 6p,
trisomy 8, and isochromosome 8q [5].
Currently, there are no effective treatments to prevent,
delay, or treat liver metastases of uveal melanoma, and
the median survival after diagnosis of liver metastasis is
2–7 months in historical series [6]. Several regional
therapies are clinically used or under investigation in
clinical trials to control liver progression, such as hepatic
arterial chemotherapy, chemoembolization [6], radio-
embolization [7], thermoablation [8], or targeted therapies
showing potential benefit on overall survival or response
rate, even without objective tumor response [4,9]. For
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instance, using intra-arterial hepatic fotemustine chemo-
therapy, median survival of up to 15 months has been
observed in association with a 36% response rate and 33%
survival rate at 2 years [10].
Positron emission tomography (PET) with 18F-fluorodeox-
yglucose (FDG) is a sensitive and an accurate method for
the detection of metastases from cutaneous melanoma. Of
limited value for the diagnosis of ocular melanoma, it was
found to be sensitive for the detection of hepatic and
extrahepatic metastases [11–14]. Servois et al. [15] com-
pared the performance of FDG-PET and MRI for staging
liver metastasis and concluded that MRI was superior to
FDG-PET, but the respective value of FDG-PET and
MRI have not been fully assessed in intrapatient
comparison for the diagnosis and monitoring of liver
metastasis from uveal melanoma [12]. Tumor uptake of
FDG is highly reproducible and decrease is known to occur
before change in size [16]. Whether this remains true for
liver metastases from uveal melanoma is not known.
Early diagnosis of liver metastasis may be important for
therapeutic management [17]. Furthermore, early re-
sponse assessment may benefit the introduction of new
treatment options as key oncogenic processes leading to
uveal melanoma have been recently identified [18]. Our
purpose was to determine the respective value of FDG-
PET and MRI in patients with liver metastases of uveal
melanoma.
Methods
Patient selection
From 2004 to 2008, 10 patients with known uveal
melanoma and at least one histologically-proven liver
metastasis were enrolled in a randomized phase III
multicentric trial from the Uveal Melanoma Group of the
European Organization for Research and Treatment of
Cancer (EORTC) comparing the effect on overall survival
of hepatic intra-arterial with systemic intravenous admin-
istration of fotemustine in patients with liver metastases
from uveal melanoma (EORTC-18021, NCT00110123).
This trial initiated after a phase II trial at our center
showed evidence for improved survival after intra-arterial
hepatic fotemustine chemotherapy [19]. The eligibility
criteria were age of more than or equal to 18 years,
surgically incurable or unresectable disease, and no
extrahepatic metastases; whereas the exclusion criteria
were previous chemotherapy or radiotherapy, abnormal
hematopoiesis, abnormal kidney or liver function, uncon-
trolled angina pectoris, myocardial infarction for less than
6 months, intracranial hypertension, other severe cardiac
disease, and other malignancy for less than 5 years.
Patients not having recovered from earlier major surgery
or with World Health Organization performance status
not more than 2 were also excluded. The protocol was
approved by the local ethics committee and the Swiss
regulatory authorities, and patients signed informed
consent forms before inclusion.
At our center, this protocol included an imaging study
comparing MRI and FDG-PET that is presented here. Ten
patients (six women, four men; 20–74 years at diagnosis)
were studied by MRI and PET/CTwithin 4 weeks (range,
0–25 days). Of them, six patients were studied at baseline
and four early during chemoinduction (after 3–4 cycles of
fotemustine). During follow-up, a subgroup of six patients
repeated both PET/CT and MRI studies within 4 weeks
after a variable time on therapy (7–28 weeks).
Magnetic resonance imaging
Abdominal MRI images were acquired on a 1.5T (n=5)
and 3T (n=5) scanner (Symphony, Siemens Healthcare,
Erlangen, Germany) with a maximum gradient strength
of 40mT/m using a four-channel phased-array body coil
with a 35 25-cm field of view, and bandwidth was
1346Hz. The liver protocol encompassed a breath-hold,
T2-weighted transverse half-Fourier single-shot turbo spin
echo sequence (repetition time/echo time=1100ms/
59ms, echo train length=256, matrix=256 148, slab
thickness/gap=3mm/0.9mm), a T1-weighted transverse
spoiled gradient-echo sequence (in-phase: 167/4.8; out-
phase: 167/2.4, 256 134, 6/2; flip angle, 701), a respira-
tory-triggered T2-weighted transverse fat-suppressed fast
spin-echo sequence (6361.3/121, echo train length=23,
512 188, 6/1.8) and a breath-hold T1-weighted trans-
verse fat-suppressed gradient-echo sequences (3.7/1.6,
256 192, 4/0.8, flip angle 121, number of excitations=
1). The latter was performed before and after intra-
venous gadolinium-diethylene triamine penta-acetic
acid (Gd-DTPA) injection (arterial, portovenous, and
equilibrium phases; 0.1mmol/kg Omniscan; GE Health-
care, Milwaukee, Wisconsin, USA). Liver lesions were
considered suspicious for metastases when presenting a
short T1 pattern (high signal intensity) without injection,
an arterial Gd-DPTA enhancement and a short T2
pattern (low signal intensity) compared with adjacent
normal liver; solitary lesions with short T1 pattern and a
long T2 pattern were also considered as suspicious [20].
18F-fluorodeoxyglucose positron emission tomography/
computed tomography
Whole-body PET/CT (Discovery LS scanner, GE Health-
care) was acquired 67±15min after intravenous bolus
injection of FDG (5MBq/kg) using standard PET/CT
acquisition protocols. Patients had been fasting for more
than or equal to 6h and blood glucose at injection was less
than 8.3mmol/l. Attenuation correction was performed
using an unenhanced CT (140keV, 80mA, 0.8 s per rotation,
table speed of 15mm/rotation, slice thickness of 5mm).
Liver lesions were considered suspicious for metastases
when FDG uptake was focally increased compared with
surrounding liver on at least two consecutive 5-mm slices.
Image analysis
An experienced radiologist evaluated the MR images and
an experienced nuclear medicine specialist evaluated the
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PET images. Each reader was blinded to the results of the
other modality. For MR, hepatic lesions were numbered,
evaluated and their largest diameter measured. For each
suspicious liver lesion, maximal standardized uptake
value (SUV) corrected for body weight was obtained. To
facilitate result comparison with other PET centers, we
expressed the lesion SUV normalized to normal liver
parenchyma SUV (‘lesion-to-liver SUV ratio’) by dividing
the lesion SUV by liver SUV averaged in a volume of more
than or equal to 27 cm3 in a region with uniform activity
on PET distant from areas with abnormally increased
or decreased FDG uptake. In a second reading, MRI
and PET images were subsequently compared with
each other to classify each lesion as being detected by
both (MR+PET) or a single modality (MRI or PET).
The intrinsically low resolution of PET scanners and
the three-dimensional voxel sampling contribute to the
‘partial volume effect,’ which significantly diminishes
the apparent SUV in lesions smaller than twice the PET
scanner resolution [21]. Therefore, referring to the known
spatial resolution of our scanner of about 6mm [22],
a subgroup analysis was performed according to lesion
size of less than 1.2 and more than or equal to 1.2 cm
diameter.
Statistical analysis
Results are presented as mean± standard deviation, if
not specified otherwise. Group comparisons were made
using unpaired Student’s t-tests for continuous variables
and the w2-test for categorical variables. Lesion changes
from baseline to follow-up used paired Student’s t-test,
and associations were sought using Pearson’s correlations.
Significance was considered for P values of less than 0.05.
Results
Patient characteristics
Table 1 summarizes patient and tumor characteristics: no
patient presented with a T1 tumor, one with a T2 (10%),
seven with a T3 (70%), and two with a T4 (20%) tumor,
according to the Tumor Node Metastasis-American Joint
Cancer Committee classification [23] and three patients
already had liver metastasis at primary diagnosis (M1).
The median interval between the primary diagnosis of
uveal melanoma and the detection of hepatic metastasis
was 3.0 years (range: 0–10 years). No significant
correlation was found between SUV on one hand and
the total number of lesions, tumor height, largest basal
diameter or Tumor Node Metastasis-American Joint
Cancer Committee classification on the other hand (all
P>0.44).
Lesion detection according to imaging modality
Overall, 108 suspicious liver lesions were seen by MRI or
PET (Table 2). Of these lesions, 34 (31%) were seen on
both PETand MRI, four (4%) only on PET, and 70 (65%)
only on MRI, among which 41 were seen in one patient
(Figs. 1 and 2). On a per-patient basis, at least one liver
metastasis (range 1–18) was detected with PET in all
patients.
Influence of lesion size
As expected, MRI more often detected small-sized
lesions, whereas most lesions of more than or equal to
1.2 cm could be seen on both modalities. Twenty six of 33
(79%) lesions of more than or equal to 1.2 cm on MRI were
visualized by PET, whereas this was the case for only eight
of 71 (11%) lesions of less than 1.2 cm (P< 0.0001).
Moreover, lesions of less than 1.2 cm had significantly
lower SUV than more than or equal to 1.2 cm lesions
(3.1±0.5 vs. 4.7±1.8 g/ml, P< 0.0001; Fig. 3).
18F-fluorodeoxyglucose positron emission tomography
standardized uptake value
For lesions detected by both modalities, there was a strong
correlation between SUV [SUV (g/ml)= 2.9+1.06 MRI
size (cm), r=0.76, P< 0.0001], as well as between the
lesion-to-liver SUV ratio (r=0.81, P< 0.0001) and MRI
lesion size (Fig. 4). Of note, there were eight subcenti-
metric lesions detected by PET with SUV significantly
increased above liver background (3.8±0.5 vs. 3.0±0.4 g/
ml, P< 0.0001; Fig. 4). PET lesions with no corresponding
MRI lesion presented significantly elevated SUV com-
pared with liver background (4.0±0.5 vs. 3.0±0.4 g/ml,
P< 0.0001; Fig. 5). MRI lesions without corresponding
PET lesion were significantly smaller (0.6±0.2 vs.
2.1±1.1 cm, P< 0.0001; Fig. 6).
Lesion monitoring during chemotherapy
Median time between baseline and follow-up imaging was
2.6 months (range, 1.5–6.5 months) in the group of six
patients imaged twice (n=30 lesions in total). As any
change in lesion size can influence the measured SUV, a
subgroup analysis was performed for lesions detected on
both MRI and PET/CTaccording to change in lesion size
(no significant change in size vs. increase in MR-
measured largest lesion diameter). The mean SUV of
liver did not change significantly from baseline to follow-
up (2.93±0.46 vs. 2.81±0.25, P=0.7). In five patients,
lesion size (26 lesions) did not change significantly,
whereas one patient (four lesions) progressed rapidly
after 3.9 months, as illustrated in Fig. 7. In stable lesions
(n=26), lesion-to-liver SUV ratio significantly decreased
(from 1.90±0.64 to 1.46±0.50, P< 0.0001), whereas in
growing lesions (n=4) lesion-to-liver SUV ratio increased
(1.56±0.40–1.99±0.56, P= 0.032).
Discussion
Our study on 10 patients with hepatic metastases from
uveal melanoma, adding together over 100 liver lesions
observed on MRI and PET, only 31% of the secondary
lesions were seen on both modalities; whereas most
lesions inferior to 1 cm were missed on FDG-PET. Our
PET and MRI in uveal melanoma metastases Orcurto et al. 3
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data therefore confirm the findings of Servois et al. [15],
showing that MRI outweighs PET/CT performance for
detecting small-sized liver metastases. In consequence,
MRI appears to be the preferred method for evaluating
number and topography of liver metastases potentially
treatable by local therapy such as surgery, radiofrequency
ablation, chemoembolization, or radioembolization. The
partial volume effect and artifacts from respiratory
movements during acquisition prevented detection of
most small-sized metastases. Nevertheless, a few infra-
centimetric lesions (11%) expressed an increased FDG
uptake. When considering larger sizes (Z 1.2 cm), 79% of
the lesions were visualized by both modalities. On a
per-patient basis, FDG-PET proved to be a sensitive
investigation, as it detected the presence of at least one
liver metastasis in every patient of our population. This
allowed changes to be observed in the metabolic activity
of lesions between baseline and follow-up examinations,
even in the absence of a change in lesion size on MRI.
Our study compared MRI with FDG-PET in the same
patient. Francken et al. [13] evaluated the detectability of
liver metastasis by PET in a cohort of 22 patients, which
showed a high sensitivity (10/10), a moderate specificity
(67%), as well as positive and negative predictive
Table 1 Patients and tumors characteristics
Tumor size (mm)b
Patient number Sex Age (years)a Eye side Height Largest basal diameter TNM-AJCC (stage) Primary tumor therapy
1 Man 73 Right 2.9 13.1 T4N0M1 (IV) Proton therapy
2 Woman 69 Left 3.1 14.2 T2N0M0 (II) Proton therapy
3 Woman 30 Left 5.8 16.3 T3N0M0 (III) Proton therapy
4 Man 39 Left 5.8 23.5 T3N0M0 (III) Proton therapy
5 Woman 20 Left 6.8 15.6 T3N0M0 (III) Proton therapy
6 Man 74 Right 7.0 7.0 T3N0M0 (III) Enucleation
7 Man 56 Left 9.0 19.0 T3N0M0 (III) Proton therapy
8 Woman 72 Right 11.4 19.1 T3N0M1 (IV) Proton therapy
9 Woman 57 Right 12.7 23.3 T3N0M1 (IV) Proton therapy
10 Woman 71 Left 16.0 15.0 T4N0M0 (III) Enucleation
AJCC, American Joint Cancer Committee Classification; TNM, tumor node metastasis.
aAt diagnosis of primary tumor.
bTumor size of tumors treated by proton therapy cannot be compared with tumor size of enucleation, as the height and largest basal diameter were measured by
ultrasound and preoperative transillumination respectively in the former and derived from the histopathology report in the latter.
Table 2 Positron emission tomography and MRI imaging findings
Patient Number of MRI lesions Number of PET lesions Number of lesions seen both on PET and MRI (%) Number of small-sized lesions [mean (range), cm]a
1 2 1 1 (50) 2 [0.9 (0.8–1.0)]
2 4 3b 2 (50) 3 [0.8 (0.5–1.0)]
3 2 2 2 (100) 0 (–)
4 41 18 18 (44) 20 [0.7 (0.3–1.1)]
5 2 2b 1 (50) 2 [0.9 (0.8–0.9)]
6 26 4 4 (15) 21 [0.5 (0.5–1.1)]
7 3 3 3 (100) 2 [0.8 (0.8–0.8)]
8 4 2b 1 (25) 3 [0.4 (0.4–0.4)]
9 8 2b 1 (13) 7 [0.5 (0.3–0.8)]
10 12 1 1 (8) 11 [0.5 (0.4–1.0)]
Total 104 38 34 (33) 71 [(0.3–1.1)]
aDefined as size < 1.2 cm, which corresponds to twice the PET/CT spatial resolution [22].
bOne PET lesion not visible on MRI.
CT, computed tomography; PET, positron emission tomography.
Fig. 1
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Lesion detectability according to imaging modality and lesion size. The
vast majority of small lesions of less than 1.2 cm, were only visualized by
MRI, whereas the larger lesions of more than or equal to 1.2 cm were
mostly visualized by both, MRI and positron emission tomography
(PET). A few lesions were only detected on PET.
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values of 88 and 100%, respectively. They concluded that
FDG-PET was particularly useful in the detection of
isolated, potentially resectable liver metastases. The
present study does not confirm these initial results, as
many more liver lesions were detected by MRI alone
(PET detection rate 33%), whereas only four lesions were
shown by FDG-PETand not by MRI. These lesions were
of limited extension (<3pixels or < 1.2 cm) and of
unknown origin (no histopathological proof was available,
as it was deemed not clinically necessary for patient
management). Thus, an artifact at PETor a false-negative
MRI cannot be excluded. MRI should therefore be
considered the method of choice for detecting liver
metastases of uveal melanoma and characterizing liver
Fig. 2
4
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0
18F-fluorodeoxyglucose positron emission tomography (PET), PET/
computed tomography (CT) fusion, unenhanced CT and MRI transaxial
images of two patients: (a) A 78-year-old man with several lesions
detected on both PET and MRI (arrows) and several smaller lesions
detected on MRI only (arrowhead) showing hypersignal on T1-
weighted fat-suppressed gradient-echo [repetition time (TR), 3.7ms;
echo time (TE), 1.6ms; flip angle, 121)]; (b) a 33-year-old woman with
one 8-mm lesion detected on both PET and MRI (arrow) showing an
hypersignal on unenhanced T1-weighted spoiled gradient-echo in-
phase (TR, 167ms; TE, 4.8ms; flip angle, 701) and out-phase (TR,
167ms; TE, 2.4ms; flip angle, 701).
Fig. 3
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Boxplot of the lesion to liver standardized uptake value (SUV) ratio,
which is significantly lower for smaller lesions ( <1.2 cm) compared
with larger lesions (Z1.2 cm; P<0.0001).
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Plot of the standardized uptake value (SUV) of the lesion-to-liver SUV
ratio versus MRI lesion size for lesions visible on both modalities. There
was a significant correlation between lesion-to-liver SUV ratio and
lesion size, even above twice the positron emission tomography/
computed tomography (PET/CT) resolution (y=0.79+0.44x, r=0.81,
P<0.0001). Note that eight lesions smaller than twice the PET/CT
resolution (1.2 cm, dashed line) were also detected on PET/CT.
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involvement potentially amenable to local therapy. Our
findings are in line with recent results by Strobel
et al. [24] showing limited value of FDG-PET in the
detection of liver metastasis from uveal melanoma
compared with cutaneous melanoma, with a PET
detection rate of only 41% (11/27 metastases).
Importantly, serial PET was able to detect short-term
changes in the metabolic activity of lesions despite the
absence of size change. This has significant implications
for the early assessment of therapy response and FDG-
PETassessment of metastases has been proposed both as
a surrogate marker of treatment response and as a
prognostic factor for overall survival [25]. Identifying
responders and nonresponders might improve clinical
management in term of side effects and costs [26].
Baseline SUV was found to be proportional to MRI size,
including lesions with dimensions well above those where
the partial volume effect is no longer expected to play
a role. In fact, larger SUV values reflect an increased rate
of glycolysis and have been strongly associated with
increased tumor aggressiveness and poorer outcome in a
number of cancers such as lung cancer, esophageal cancer,
or thyroid carcinoma [25,27]. Whether baseline SUV
remains an independent prognostic marker in addition to
the largest dimension of liver metastases needs to be
verified in an outcome study following published guide-
lines [28].
Obviously, the small size and heterogeneity of our patient
population does not allow to evaluate the effect of
treatment response according to the administration route
or chemotherapeutic regimen, which is the aim of the
multicentric EORTC-18021 study, but with over 100
lesions, comparisons between MRI and PET can be
considered valid. Four patients had already started
chemotherapy at first PET, which may diminish PET
Fig. 5
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Boxplot of the ratio of lesion standardized uptake value (SUV) to liver
parenchyma SUV according to visualization by MRI+positron emission
tomography (PET) or PET alone. The lesion-to-liver SUV ratio of lesions
visible by both modalities (MRI +PET) was significantly higher than
unity (P<0.0001).
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Boxplot of the lesion size according to visualization by MRI+positron
emission tomography (PET) or MRI alone. The diameter of lesions
visible by both modalities (MRI +PET) was significantly larger than
lesions visible only by MRI (P<0.0001).
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Variation in lesion-to-liver standardized uptake value (SUV) ratio
between baseline [positron emission tomography (PET 1)] and follow-
up study (PET 2) according to change in lesion size as measured by
MRI, no change vs. increase in size for patients with lesions visible on
both 18F-fluorodeoxyglucose-PET and MRI at baseline (six patients, 30
lesions in total).
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sensitivity. Another potential limitation is that the
diagnosis of metastatic liver lesions was based on their
characteristic MRI appearance, as it is obviously not
possible to biopsy all liver lesions. Thus, false-positive
lesions at MRI cannot be excluded, but the combination
of T1 weighting and T2 weighting, and behavior after
gadolinium-diethylene triamine pentaacetic acid injec-
tion increase specificity. For a few patients, a dual-phase
PET/CT was performed with a late phase taken after
90min or more, which seemed to improve lesion
detectability by increasing lesion SUV and lesion-to-liver
SUV ratio (data not shown); delayed FDG-PET acquisi-
tion might therefore improve the detection of small
metastases, as has been demonstrated for several other
tumors as well as primary uveal melanomas [14]. Diffu-
sion-weighted MRI was not performed in this study, but
might be valuable in assessing response to therapy, if
preliminary results showing treatment related changes in
the apparent diffusion coefficient are confirmed [29].
Finally, our pilot study was not designed to determine the
predictive value of PET or MRI for therapy response.
Conclusion
In this pilot study, MRI outweighs FDG-PET perfor-
mance for detecting small-sized liver metastases and is
therefore the preferred method for diagnosing the
number and the topography of liver metastases. However,
PET/CTshowed a decreased FDG uptake in the absence
of MRI change under chemotherapy and an increased
FDG uptake in lesions increasing in size at follow-up
suggesting a possible role for monitoring treatment
response. This underlines the need of determining the
value of FDG-PET/CT in predicting long-term response
to therapy in patients with liver metastases from uveal
melanoma in a prospective study.
Acknowledgements
This study had no financial support. J.O.P. was recipient
of an Academic Research Award from the Leenaards
Foundation (Lausanne, Switzerland).
Conflicts of interest
There are no conflicts of interest.
References
1 Mudhar HS, Parsons MA, Sisley K, Rundle P, Singh A, Rennie IG. A critical
appraisal of the prognostic and predictive factors for uveal malignant
melanoma. Histopathology 2004; 45:1–12.
2 Singh AD, Topham A. Incidence of uveal melanoma in the United States:
1973–1997. Ophthalmology 2003; 110:956–961.
3 Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, et al.
Incidence of uveal melanoma in Europe. Ophthalmology 2007; 114:
2309–2315.
4 Bakalian S, Marshall JC, Logan P, Faingold D, Maloney S, Di Cesare S, et al.
Molecular pathways mediating liver metastasis in patients with uveal
melanoma. Clin Cancer Res 2008; 14:951–956.
5 Damato B, Dopierala J, Klaasen A, Van Dijk M, Sibbring J, Coupland SE.
Multiplex ligation-dependent probe amplification of uveal melanoma:
correlation with metastatic death. Invest Ophthalmol Vis Sci 2009;
50:3048–3055.
6 Feldman ED, Pingpank JF, Alexander HR Jr. Regional treatment options for
patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 2004;
11:290–297.
7 Kennedy AS, Nutting C, Jakobs T, Cianni R, Notarianni E, Ofer A, et al. A first
report of radioembolization for hepatic metastases from ocular melanoma.
Cancer Invest 2009; 27:682–690.
8 Kuvshinoff B, Fong Y. Surgical therapy of liver metastases. Semin Oncol
2007; 34:177–185.
9 Triozzi PL, Eng C, Singh AD. Targeted therapy for uveal melanoma. Cancer
Treat Rev 2008; 34:247–258.
10 Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, et al.
Intra-arterial hepatic fotemustine for the treatment of liver metastases from
uveal melanoma: experience in 101 patients. Ann Oncol 2006; 17:
578–583.
11 Reddy S, Kurli M, Tena LB, Finger PT. PET/CT imaging: detection of
choroidal melanoma. Br J Ophthalmol 2005; 89:1265–1269.
12 Kurli M, Reddy S, Tena LB, Pavlick AC, Finger PT. Whole body
positron emission tomography/computed tomography staging of
metastatic choroidal melanoma. Am J Ophthalmol 2005; 140:
193–199.
13 Francken AB, Fulham MJ, Millward MJ, Thompson JF. Detection of metastatic
disease in patients with uveal melanoma using positron emission
tomography. Eur J Surg Oncol 2006; 32:780–784.
14 Beyer T, Pietrzyk U, Knoess C, Vollmar S, Wienhard K, Kracht L, et al.
Multi-modality imaging of uveal melanomas using combined PET/CT,
high-resolution PET and MR imaging. Nuklearmedizin 2008; 47:73–79.
15 Servois V, Mariani P, Malhaire C, Petras S, Piperno-Neumann S, Plancher C,
et al. Preoperative staging of liver metastases from uveal melanoma by
magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron
emission tomography (FDG-PET). Eur J Surg Oncol 2010; 36:189–194.
16 Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M.
Reproducibility of metabolic measurements in malignant tumors using
FDG PET. J Nucl Med 1999; 40:1771–1777.
17 Aoyama T, Mastrangelo MJ, Berd D, Nathan FE, Shields CL, Shields JA, et al.
Protracted survival after resection of metastatic uveal melanoma. Cancer
2000; 89:1561–1568.
18 Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S,
Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med
2010; 363:2191–2199.
19 Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, et al.
Treatment of ocular melanoma metastatic to the liver by hepatic arterial
chemotherapy. J Clin Oncol 1997; 15:2589–2595.
20 Maeda T, Tateishi U, Suzuki S, Arai Y, Kim EE, Sugimura K. Magnetic
resonance screening trial for hepatic metastasis in patients with
locally controlled choroidal melanoma. Jpn J Clin Oncol 2007; 37:
282–286.
21 Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging.
J Nucl Med 2007; 48:932–945.
22 Bolard G, Prior JO, Modolo L, Delaloye AB, Kosinski M, Wastiel C, et al.
Performance comparison of two commercial BGO-based PET/CT scanners
using NEMA NU 2-2001. Med Phys 2007; 34:2708–2717.
23 American Joint Committee on Cancer. Malignant melanoma of the uvea
AJCC Cancer Staging Manual. 6th edn. New York, NY: Springer. 2002;
pp. 365–370.
24 Strobel K, Bode B, Dummer R, Veit-Haibach P, Fischer D, Imhof L, et al.
Limited value of 18F-FDG PET/CT and S-100B tumour marker in the
detection of liver metastases from uveal melanoma compared to liver
metastases from cutaneous melanoma. Eur J Nucl Med Mol Imaging 2009;
36:1774–1782.
25 Larson SM, Schwartz LH. 18F-FDG PET as a candidate for ‘qualified
biomarker’: functional assessment of treatment response in oncology. J Nucl
Med 2006; 47:901–903.
26 Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, et al.
Early prediction of response to sunitinib after imatinib failure
by 18F-fluorodeoxyglucose positron emission tomography in
patients with gastrointestinal stromal tumor. J Clin Oncol 2009;
27:439–445.
27 Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, et al.
Preoperative F-18 fluorodeoxyglucose-positron emission tomography
maximal standardized uptake value predicts survival after lung cancer
resection. J Clin Oncol 2004; 22:3255–3260.
28 Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA,
et al. Consensus recommendations for the use of 18F-FDG PET as an
indicator of therapeutic response in patients in National Cancer Institute trials.
J Nucl Med 2006; 47:1059–1066.
29 Buijs M, Vossen JA, Hong K, Georgiades CS, Geschwind JF, Kamel IR.
Chemoembolization of hepatic metastases from ocular melanoma:
assessment of response with contrast-enhanced and diffusion-
weighted MRI. AJR Am J Roentgenol 2008; 191:285–289.
PET and MRI in uveal melanoma metastases Orcurto et al. 7
